Melanoma (Skin)
Conditions
Brief summary
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
Detailed description
While melanoma risk is largely genetically determined, exposure to ultraviolet (UV) radiation in sunlight is the major environmental risk factor. Although sunscreen use can reduce melanoma risk 2-fold, its efficacy has been questioned, and most patients do not apply sunscreens properly. This study will evaluate the downstream effects of aspirin (ASA) in human blood and skin moles (nevi) following oral ingestion. We will determine if chronic ingestion of ASA can modulate UV-sensitivity of the skin, UV-induced damage in nevi, and PGE2 levels in blood and nevi.
Interventions
DRUGAspirin 81 mg
Participants will be given ASA 81 mg orally once daily for a total of 60 days
DRUGAspirin 325mg
Participants will be given ASA 325 mg orally once daily for a total of 60 days
DRUGPlacebo oral tablet
Participants will be given placebo orally once daily for a total of 60 days
Sponsors
University of Utah
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must have at least 2 nevi (each \>5 mm diameter) not clinically suspicious for melanoma that can be biopsied. * Must be older than age 18. * Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.
Exclusion criteria
* The patient cannot speak / understand English or Spanish. * The patient is pregnant or breastfeeding. * The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable. * The patient has history of allergic reaction to ASA. * The patient has history of severe asthma. * The patient has been taking ASA or any NSAID in the past 2 weeks. * The patient has been taking a blood thinner in the past 2 weeks. * The patient has history of bleeding disorder. * The patient has history of peptic ulcer disease. * The patient has had recent intense UV exposure in the past month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in minimal erythemal dose (MED) from baseline to day 60. | Change from baseline to day 60 | Baseline minimal erythemal dose (MED) measurements will will be compared to MED results at day 60. We will use the conventional definition of MED as the lowest UV dose resulting in erythema that completely fills the 8-mm irradiated site (homogeneous erythema). |
| Change in concentration of prostaglandin E2 (PGE2) in plasma from baseline to day 60. | Change from baseline to day 60 | Baseline PGE2 levels in plasma specimens will be compared to PGE2 levels at day 60. |
| Change in concentration of prostaglandin E2 (PGE2) in nevus tissue from baseline to day 60. | Change from baseline to day 60 | Baseline PGE2 levels in tissue specimens will be compared to PGE2 levels at day 60. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in concentration of oncometabolite 2-hydroxyglutarate (2-HG) in plasma from baseline to day 60. | Change from baseline to day 60 | Baseline 2-HG levels in plasma specimens will be compared to 2-HG levels at day 60. |
| Change in concentration of 8-oxoguanine (8-OG) in nevus tissue from baseline to day 60. | Change from baseline to day 60 | Baseline 8-OG levels in tissue specimens will be compared to 8-OG levels at day 60. |
| Change in concentration of 8-oxoguanine (8-OG) in plasma from baseline to day 60. | Change from baseline to day 60 | Baseline 8-OG levels in plasma specimens will be compared to 8-OG levels at day 60. |
| Change in concentration of oncometabolite 2-hydroxyglutarate (2-HG) in nevus tissue from baseline to day 60. | Change from baseline to day 60 | Baseline 2-HG levels in tissue specimens will be compared to 2-HG levels at day 60. |
Countries
United States
Outcome results
None listed